Department of Breast Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Clin Transl Oncol. 2023 Jul;25(7):1869-1892. doi: 10.1007/s12094-023-03189-3. Epub 2023 Apr 17.
Breast cancer (BC) leads to the most amounts of deaths among women. Chemo-, endocrine-, and targeted therapies are the mainstay drug treatments for BC in the clinic. However, drug resistance is a major obstacle for BC patients, and it leads to poor prognosis. Accumulating evidences suggested that noncoding RNAs (ncRNAs) are intricately linked to a wide range of pathological processes, including drug resistance. Till date, the correlation between drug resistance and ncRNAs is not completely understood in BC. Herein, we comprehensively summarized a dysregulated ncRNAs landscape that promotes or inhibits drug resistance in chemo-, endocrine-, and targeted BC therapies. Our review will pave way for the effective management of drug resistance by targeting oncogenic ncRNAs, which, in turn will promote drug sensitivity of BC in the future.
乳腺癌（BC）是导致女性死亡人数最多的癌症。化疗、内分泌和靶向治疗是临床上治疗 BC 的主要药物治疗方法。然而，耐药性是 BC 患者的主要障碍，导致预后不良。越来越多的证据表明，非编码 RNA（ncRNA）与包括耐药性在内的广泛病理过程密切相关。迄今为止，BC 中耐药性与 ncRNA 之间的相关性尚未完全阐明。在此，我们全面总结了促进或抑制化疗、内分泌和靶向 BC 治疗中耐药性的失调 ncRNA 图谱。我们的综述将为通过靶向致癌 ncRNA 有效管理耐药性铺平道路，这反过来又将促进未来 BC 的药物敏感性。
